Instructions for providing comments[edit source]
Click “Reply” in the bottom right corner and an empty comment box will open. The exact wording of your comment will appear in the discussion thread, but cannot be edited by other reviewers.
2) Copy and paste the sentence/paragraph to which your feedback relates, leave a blank line and then include your comment or suggested change.
3) Statements regarding the inclusion/exclusion of issues should be clearly supported by scientific evidence, and specifically outline the relevance of the suggested material to the guidelines.
Full citation of the reference/s should be provided for consideration.
4) If you have identified any gaps or errors in the content please suggest suitable text for inclusion.
5) Please highlight any terms that need to be defined in the Glossary.
DON’T FORGET TO SAVE YOUR COMMENT!
It is hoped that 177Lu-octreotate will shortly become available on more favourable terms through the Australian Nuclear Science and Technology Organisation (ANSTO).
ANSTO has recently announced an agreement to import 177Lu from a German company, but unfortunately at an even greater cost than from IDB. It will be a few years before ANSTO is producing and selling its own 177Lu.
Richard Smart St George Hospital, Kogarah firstname.lastname@example.org
COSA on behalf of Gabrielle Cehic and Steven Unger (Flinders Medical Centre, SA)
- reference centres
Comment: Should this read: referral centres.
- It is planned that patients with progressive, disseminated, unresectable, low grade GEP-NETs, with appropriate somatostatin receptor avidity demonstrated on diagnostic somatostatin receptor imaging, including 111In-Octreotide SPECT or 68Ga-somatostatin analogue PET studies, will be referred to the State reference centre for radiopeptide treatment.
Comment: Recommend adding Lutetium-177 Octreotide SPECT as a third indicator.
- 177LuCl3 is commercially available to Australasian patients directly imported from Europe (IDB, Baarle-Nassau, NL). It is hoped that 177Lu-octreotate will shortly become available on more favourable terms through the Australian Nuclear Science and Technology Organisation (ANSTO). The use of identified reference centres would facilitate both gathering of data and national randomised controlled trials using 177Lu-octreotate, with or without radiosensitising chemotherapy.
Comment: A consistent reliable source is needed (i.e. IDB). ANSTO will not be producing sufficient quantity anywhere in the near future, and is likely to be very expensive.